#### **Evolution of immunity to SARS-CoV-2** 1

2

3 4 5 6 7 8	Adam K. Wheatley <sup>1,2*</sup> , Jennifer A. Juno <sup>1*</sup> , Jing J. Wang <sup>3*</sup> , Kevin J. Selva <sup>1</sup> , Arnold Reynaldi <sup>4</sup> , Hyon-Xhi Tan <sup>1</sup> , Wen Shi Lee <sup>1</sup> , Kathleen M. Wragg <sup>1</sup> , Hannah G. Kelly <sup>1,2</sup> , Robyn Esterbauer <sup>1,2</sup> , Samantha K. Davis <sup>1</sup> , Helen E. Kent <sup>1,5</sup> , Francesca L. Mordant <sup>1</sup> , Timothy E. Schlub <sup>4,6</sup> , David L. Gordon <sup>7</sup> , David S. Khoury <sup>4</sup> , Kanta Subbarao <sup>1,8</sup> , Deborah Cromer <sup>4</sup> , Tom P. Gordon <sup>3,9</sup> , Amy W. Chung <sup>1</sup> , Miles P. Davenport <sup>4</sup> , Stephen J. Kent <sup>1,2,5</sup> .
9 10 11 12	*AKW, JAJ and JJW contributed equally
13 14	<sup>1</sup> Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
15 16	<sup>2</sup> Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, Victoria, Australia
17 18 19	<sup>3</sup> Department of Immunology and Flinders Proteomics Facility, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia
19 20 21	<sup>4</sup> Kirby Institute, University of New South Wales, Kensington, New South Wales, Australia
22 23 24	<sup>5</sup> Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Victoria, Australia
25 26 27	<sup>6</sup> Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
28 29 30	<sup>7</sup> Department of Microbiology and Infectious Diseases, Flinders University and SA Pathology, Flinders Medical Centre, Adelaide, South Australia, Australia
30 31 32	<sup>8</sup> WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
33 34 35	<sup>9</sup> Department of Immunology, SA Pathology, Flinders Medical Centre, Adelaide, South Australia, Australia
36 37 38	Corresponding author. Address to Professor Stephen Kent, Department of Microbiology and Immunology, Doherty Institute, 792 Elizabeth St, Melbourne, Victoria, Australia 3000. Phone +61 3 8344 9939. Email: <u>skent@unimelb.edu.au</u>
39	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

40

41 The durability of infection-induced SARS-CoV-2 immunity has major implications for public health mitigation and vaccine development. Animal studies<sup>1,2</sup> and the 42 43 scarcity of confirmed re-infection<sup>3</sup> suggests immune protection is likely, although the 44 durability of this protection is debated. Lasting immunity following acute viral 45 infection requires maintenance of both serum antibody and antigen-specific memory 46 B and T lymphocytes and is notoriously pathogen specific, ranging from life-long for 47 smallpox or measles<sup>4</sup>, to highly transient for common cold coronaviruses  $(CCC)^5$ . 48 Neutralising antibody responses are a likely correlate of protective immunity and 49 exclusively recognise the viral spike (S) protein, predominantly targeting the receptor 50 binding domain (RBD) within the S1 sub-domain<sup>6</sup>. Multiple reports describe waning of S-specific antibodies in the first 2-3 months following infection<sup>7-12</sup>. However, 51 52 extrapolation of early linear trends in decay might be overly pessimistic, with several 53 groups reporting that serum neutralisation is stable over time in a proportion of 54 convalescent subjects<sup>8,12-17</sup>. While SARS-CoV-2 specific B and T cell responses are readily induced by infection<sup>6,13,18-24</sup>, the longitudinal dynamics of these key memory 55 56 populations remains poorly resolved. Here we comprehensively profiled antibody, B 57 and T cell dynamics over time in a cohort recovered from mild-moderate COVID-19. 58 We find that binding and neutralising antibody responses, together with individual 59 serum clonotypes, decay over the first 4 months post-infection, as expected, with a 60 similar decline in S-specific CD4+ and circulating T follicular helper (cTFH) 61 frequencies. In contrast, S-specific IgG+ memory B cells (MBC) consistently 62 accumulate over time, eventually comprising a significant fraction of circulating 63 MBC. Modelling of the concomitant immune kinetics predicts maintenance of 64 serological neutralising activity above a titre of 1:40 in 50% of convalescent subjects 65 to 74 days, with probable additive protection from B and T cells. Overall, our study

- 2 -

66	suggests SARS-CoV-2 immunity after infection is likely to be transiently protective at
67	a population level. SARS-CoV-2 vaccines may require greater immunogenicity and
68	durability than natural infection to drive long-term protection.
69	
70	We recruited a longitudinal cohort of 64 subjects who recovered from COVID-19
71	(Extended Data Fig 1). A total of 158 samples were collected between day 26 and 149
72	post-symptom onset, with samples nominally denoted as early ( $\leq$ 50days),
73	intermediate (50-100 days) and late (≥100 days) convalescence (Fig 1A). In early
74	convalescence, neutralisation activity was widespread with a median serological titre
75	of 52, which declined to 34 in late convalescence (Fig 1B). A mixed-effects
76	modelling approach found that a two-phase decay model best fit with the observed
77	decay of neutralisation titres across the cohort ( $p < 0.00001$ , likelihood ratio test), with
78	rapid decay evident over the first half of our time-series (half-life $(t_{1/2})$ prior to day 70
79	= 55 days), compared with slower decay in the second half ( $t_{1/2}$ from day 70 = 519
80	days)(Fig 1B). The capacity of immune plasma to inhibit interaction of the SARS-
81	CoV-2 receptor binding domain (RBD) with soluble hACE2 receptor <sup>19</sup> waned with a
82	similar two-phase decay, dropping more rapidly before day 70 ( $t_{1/2} = 238$ days) and
83	slowing after day 70 ( $t_{1/2} = 1912$ days; Fig1C).
84	

85 Plasma antibodies specific for SARS-CoV-2 S antigens (trimeric spike protein (S),

86 S1, S2 and RBD subdomains) and nucleocapsid (N) antigens were quantified

87 longitudinally using a multiplex bead array<sup>25</sup>. In contrast to neutralisation titres, decay

88 of S-specific IgG was best fit by a model of constant decay over the period of

89 observation ( $t_{1/2} = 229$  days), with rates of decay divergent for antibodies binding S1

90 ( $t_{1/2}$ =115 days), S2 ( $t_{1/2}$ = 344 days) and RBD antigens ( $t_{1/2}$ = 126; Fig 1D, Extended

- 3 -

91	Data Fig. 2). Kinetics of decay were broadly consistent between IgG1 and IgG2
92	subclasses, with IgG3 displaying a more rapid, two phase decline (Extended Data Fig.
93	2). Consistent with a previous report <sup>26</sup> , we find N-specific IgG decays significantly
94	more rapidly than S-specific IgG (t <sub>1/2</sub> = 71 and 229 days respectively, $p < 0.00001$ ,
95	Fig 1D). In contrast to IgG, S-specific IgM and IgA1 fit a two-phase decay, with a
96	more rapid early decay ( $t_{1/2} = 55$ and 42 days respectively) followed by a slower
97	decay in late convalescence ( $t_{1/2} = 118$ and >1000 days respectively; Fig 1D). A
98	comparison of decay rates between neutralising activity and antibody binding
99	demonstrated that early neutralisation decay occurs at a similar rate to the early
100	decline in S, RBD and S1-specific IgM (Fig 1E, Extended Data Fig 2). Neutralisation
101	titre at both early and late convalescence was well correlated with serum inhibition of
102	RBD-ACE2 binding and S, S1 and RBD specific IgG, IgM (and to a lesser extent
103	IgA1) responses, as well as with S2 and N specific IgG responses (Extended Data Fig
104	3). Neutralising activity during early convalescence was the best correlate of long-
105	term maintenance of neutralisation responses (Spearman rho=0.88, p<0.00001;
106	Extended Data Fig 3). Serum inhibition of RBD-ACE2 binding and S1-specific IgG
107	responses in early infection were also well correlated with neutralisation titre in late
108	convalescence (Spearman rho=0.79, 0.81, respectively; Extended Data Fig 3).
109	However, in a multiple regression model, once early neutralisation activity was
110	included no other significant predictors were identified (p>0.15 for all other
111	variables).
112	
113	The decay of polyclonal antibody in plasma may obscure a more complex picture of

decay at the level of a single clonotype, we adapted a novel mass spectrometry (MS)-

114

- 4 -

the dynamics of individual antibody specificities. To resolve longitudinal serological

based quantitative proteomics workflow developed for serum autoantibody
profiling<sup>27,28</sup> to track unique CDR-H3 peptides matching recovered S-specific
immunoglobulins sequences from convalescent subjects<sup>19</sup> (n=4; Extended Data Fig
4A, B). Consistent with the decay of polyclonal S-specific antibody in the blood, we
find a decline in the relative abundance over time for each unique clonotype
(Extended Data Fig. 4C), although absolute rates of decay did vary, suggesting the
kinetics might to some degree be clonotype-, epitope- or subject-specific.

123

124 Anti-viral memory B and T cell responses will likely make additive contributions to 125 long-term immunological protection against COVID-19. SARS-CoV-2-specific B cell 126 responses were measured longitudinally in 31 subjects where sufficient cells were 127 available (Fig 1A) using flow cytometry and fluorescent S and RBD probes as previously described<sup>19</sup>. Following infection, frequencies of IgG+ S-specific memory 128 129 B cells increased over time irrespective of disease severity (Fig. 2A and 2B; gating in 130 Supplementary Fig. S1). In contrast, S-specific IgA+ MBC frequencies remained 131 relatively stable while IgM+ MBC frequencies decreased (Fig. 2B). IgG+ S-specific 132 MBC remain significantly elevated at the final relative to the first available sampling 133 (p<0.0001), contrasting with stable IgA+ (p=0.367) and declining IgM+ populations (p<0.0001) (Fig. 2C). Assessment of the activation status of S-specific IgG+ MBC 134 using CD21/CD27 staining<sup>29</sup> demonstrated decreased proportions of "activated" MBC 135 136 and a return to a resting (CD27+CD21+) phenotype over time (Extended Data Fig 5). 137 Although present at comparatively low frequencies, the dynamics of RBD-specific 138 MBC largely mirrored that of the parental S-specific population (Extended Data Fig 139 6). Modelling the growth rates reveals IgG+ S-specific MBC frequencies had a doubling time of 48 days in early convalescence, after which point the doubling time 140

141 slowed to 843 days, with IgG+ RBD-specific cells MBC broadly comparable 142 (doubling time = 58 days early,  $t_{1/2}$  = 247 days late) (Extended Data Fig 7). The 143 consistent and sustained increase in S-specific IgG+ MBC frequencies over time 144 aligns with a prior report of SARS-CoV-2 convalescent subjects<sup>13</sup>, and with reports from other viral infections<sup>30</sup> or replicating viral vaccines <sup>31,326</sup>. Given the relatively 145 146 low level of somatic mutation observed in S-specific antibodies recovered from convalescent subjects to date<sup>6,19</sup> comparative studies at 6-9 months post-infection will 147 be informative to understand the maturation of the humoral response over time and 148 149 the protective potential of stably retained MBC populations.

150

151 Anti-viral memory T cell responses have been associated with amelioration of disease for respiratory infection such as influenza<sup>33</sup>. S-specific cTFH and conventional CD4+ 152 153 and CD8+ memory T cells (Tmem), were quantified using activation induced marker (AIM) assays <sup>19,22</sup> (Methods) following stimulation with overlapping S (split into S1 154 155 or S2) peptide pools (Fig. 3A, 3B). Frequencies of S-specific memory T cells were 156 dynamic over time and varied between individuals, with evidence of either rapid 157 decline or stable maintenance (Fig. 3C). Pairwise comparison of cTFH or CD4+ 158 Tmem frequencies at the final visit relative to the first available sampling 159 demonstrated a significant reduction in S-specific responses over time (p=0.0031 for 160 cTFH, p=0.0224 for CD4+ Tmem; Fig. 3D). In contrast, frequencies of S-specific 161 CD8+ Tmem were stable at a population level (p=0.3247), although individual responses were varied (Fig. 3D). Modelling of the decay rates estimated  $t_{1/2}$  of 128 162 163 days for cTFH (95% CI 67, 1247) and 119 days for CD4+ Tmem (95% CI 66, 612; 164 Extended Data Fig 8). In contrast, the estimated decay of CD8+ responses is not significantly different from 0 ( $t_{1/2} = 670$  days, 95% CI 97, -136; Extended Data Fig 8). 165

- 6 -

Therefore, while we and others<sup>34,35</sup> find that CD4+ responses are generally higher
during early convalescence, CD8+ T cell responses appear relatively stable during late
convalescence.

169

170 Multiple studies have reported CCC cross-reactive CD4+ T cells in SARS-CoV-2

171 uninfected subjects, largely recognising epitopes in  $S2^{22,35,36}$ . To understand the

172 influence that recall of pre-existing CCC cross-reactive immunity might have on

173 decay, we contrasted S1 and S2 responses among the CD4+ T cell subsets. For cTFH,

a significant drop in S1 responses was observed over time (p=0.0028), while S2

175 responses were comparably stable but did similarly trend downward (p=0.0657)

176 (Extended Data Fig 9A,B). Analogous patterns were observed for the CD4+ Tmem

177 cells (Extended Data Fig 9C,D). Consequently, S2-specific cTFH and CD4+ Tmem

populations predominated over S1-directed responses (p=0.0147 and p=0.0021

179 respectively) in late convalescence (Extended Data Fig 9B,D).

180

181 Polyclonal T cell responses to S comprise an array of immunodominant and

182 subdominant epitopes; we therefore additionally tracked single CD4+ T cell epitopes

183 in a subset of 9 donors (Extended Data Fig 10A). Strikingly, we observed substantial

184 inter- and intra-individual variability in longitudinal epitope-specific responses

185 (Extended Data Fig 10B,C); in some subjects, all epitope-specific responses tracked

186 similarly while in others distinct epitope-specific responses would vary independently

187 over time. In most, but not all, cases, peptide responses tracked similarly between the

188 cTFH and Tmem populations (Extended Data Fig 10C). Overall, some degree of T

189 cell immunity remains readily detectable in most subjects 4 months after infection,

190 although longitudinal epitope-specific frequencies were markedly less predictable.

- 7 -

191

192	Deconvoluting the protective potential of the suite of concomitant immune responses
193	elicited by SARS-CoV-2 infection is challenging. The general decline of serological
194	immunity over time (Fig 4A) was similarly observed for most memory immune cell
195	subsets except for IgG+ and IgA+ MBC populations (Fig 4B). Importantly, rates of
196	immune decay are likely to stabilise over time to levels of homeostatic maintenance <sup>37</sup> ,
197	although this set point is not yet clear for SARS-CoV-2. Neutralising antibody is the
198	most widely accepted protective correlate against a range of human respiratory
199	viruses <sup>38</sup> . However, any relationship between <i>in vitro</i> neutralisation titres and <i>in vivo</i>
200	protection for SARS-CoV-2 is unclear at present. We therefore developed a
201	simulation model (see Methods) employing the estimated initial distributions of
202	neutralisation titres and decay rates across subjects, to predict the time for titres to
203	drop below a nominated cut-off of 1:40, selected based on the 1:40 hemagglutination
204	inhibition titre (a surrogate for neutralisation activity) widely used as the 50%
205	protective titre for influenza <sup>39</sup> . Notably, 43% of our cohort were already below this
206	threshold in early convalescence, with 64% of subjects dropping below this threshold
207	in late convalescence. Simulating a population of 1000 individuals, and running the
208	model 1000 times, we find the median time for 50% of the population to drop below a
209	titre of 1:40 was 74 days (Fig 4C; 95% confidence interval 46 to >1000 days).
210	Assuming early neutralisation titres predicted titres into late convalescence, our
211	simulation also allows us to estimate how higher initial levels of neutralisation may
212	affect the proportion of individuals maintaining titres above 1:40. We found that if
213	aiming for a median of 50% of individuals with a titre above 1:40 at one year, initial
214	neutralisation titres at about day 30 would need to be in the order of 2.1-fold higher
215	than that observed in our convalescent cohort (95% $CI = no$ increase to 16.9-fold

- 8 -

216 increase required). It is important to emphasise that at present the in vitro 217 neutralisation titre required and the additive contribution of other immune responses 218 to protective immunity are unknown. In addition, our analysis assumes that immunity 219 to vaccination decays at a similar rate to infection, and that the decay of neutralisation 220 titre from day 70 to around 140 predicts immune decay over the first year. Despite the 221 limitations inherent in these assumptions, this analysis provides an approach to 222 estimating the target level of immune response necessary for effective vaccination. 223 224 Overall, we find that both neutralising and binding antibody responses decay as

225 expected after recovery from COVID-19, assessed using polyclonal assays and at the 226 level of single clonotypes. While incredibly durable protective antibody responses 227 have been reported for other viral infections such as measles and smallpox<sup>4</sup>, our data 228 suggests that SARS-CoV-2 is more likely to mirror immunity to endemic CCC, where 229 serum antibody responses decline with a likelihood of increasing susceptibility to 230 homologous virus within 1-2 years<sup>5</sup>. Neutralising antibody is a presumed but not yet 231 proven correlate of immune protection for SARS-CoV-2. Assuming similar immune 232 kinetics, our modelling suggests SARS-CoV-2 vaccines would likely need to elicit 233 substantially more potent neutralising titres than infection to induce durable 234 protection. Encouragingly, many early vaccine candidates have exceeded this metric 235 when compared against sera from convalescent subjects in clinical trials reported to 236 date<sup>40,41</sup>. Persistence of serum antibody is unlikely to be the sole determinant of long-237 lasting immunity, with anamnestic recall of stably maintained memory T and B cell 238 populations likely reducing infection or disease. The magnitude, quality and 239 protective potential of cellular responses against SARS-CoV-2 requires further 240 definition. Although T cell memory in the blood contracts several months post

- 9 -

- infection, a rise in S-specific IgG+ memory B cells to a median level of ~0.8% of all
- 242 IgG+ memory B cells by 4 months suggests even mild-moderate COVID-19 induces
- substantial cellular immune memory.
- 244

#### 245 Materials and Methods

246 Ethics Statement

The study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689) and the Southern Adelaide Clinical Human Research Ethics Committee (#39.034), and all associated procedures were carried out in accordance with the approved guidelines. All participants provided written informed consent in accordance with the Declaration of Helsinki.

#### 252 Subject recruitment and sample collection

Subjects who had recovered from COVID-19 were recruited through contacts with the investigators and invited to provide serial blood samples. Subject characteristics of SARS-CoV-2 convalescent subjects are collated in Extended Data Fig 1. For all participants, whole blood was collected with sodium heparin anticoagulant. Plasma was collected and stored at -80°C, and PBMCs were isolated via Ficoll-Paque

separation, cryopreserved in 10% DMSO/FCS and stored in liquid nitrogen.

259

#### 260 Microneutralisation Assay

- 261 SARS-CoV-2 isolate CoV/Australia/VIC01/2020<sup>42</sup> was passaged in Vero cells and
- stored at -80C. Plasma was heat-inactivated at 56°C for 30 min. Plasma was serially-
- diluted 1:20 to 1:10240 before addition of 100 TCID<sub>50</sub> of SARS-CoV-2 in
- 264 MEM/0.5% BSA and incubation at room temperature for 1 hour. Residual virus
- 265 infectivity in the plasma/virus mixtures was assessed in quadruplicate wells of Vero

266 cells incubated in serum-free media containing 1  $\mu$ g/ml TPCK trypsin at 37°C/5% 267 CO2; viral cytopathic effect was read on day 5. The neutralising antibody titre is 268 calculated using the Reed/Muench method as previously described<sup>43,44</sup>. All samples 269 were assessed in two independent microneutralisation assays.

270 271

# **Expression of SARS-CoV-2 proteins**

A set of proteins was generated for serological and flow cytometric assays. The 272 273 ectodomain of SARS-CoV-2 (isolate WHU1; residues 1 – 1208) was synthesised with 274 furin cleavage site removed and P986/987 stabilisation mutations<sup>45</sup>, a C-terminal T4 275 trimerisation domain, Avitag and His-tag, expressed in Expi293 cells and purified by 276 Ni-NTA affinity and size-exclusion chromatography using a Superose 6 16/70 column 277 (GE Healthcare). SARS-CoV S was biotinylated using Bir-A (Avidity). The SARS-278 CoV-2 RBD<sup>46</sup> with a C-terminal His-tag (residues 319-541; kindly provided by 279 Florian Krammer) was similarly expressed and purified.

280

# 281 SARS-CoV-2 bead-based multiplex assay

282 The isotypes and subclasses of SARS-CoV-2 specific antibodies were detected as

283 previously described<sup>25</sup>. Briefly, a panel of SARS-CoV-2 antigens including trimeric

284 S, S1 (Sino Biological), S2 (ACROBiosystems), NP (ACROBiosystems,) and RBD<sup>46</sup>

285 were coupled to magnetic COOH- bioplex beads (Biorad) using a two-step

286 carbodiimide coupling reaction. 20µl of bead mixture containing 1000 beads per

region and 20µl of 1:200 diluted plasma were added per well. SARS-CoV-2- specific

antibodies were detected using phycoerythrin (PE)-conjugated mouse anti-human

pan-IgG, IgG1, IgG2, IgG3, IgA1 or IgA2 (Southern Biotech) at 1.3µg/ml, 25µl per

- 290 well. For the detection of IgM, biotinylated mouse anti-human IgM (mAb MT22;
- 291 MabTech) was added at 1.3µg/ml, 25µl per well followed by streptavidin-PE (SA-PE;

- 11 -

292 Thermo Fisher) at 1µg/ml. Plates were acquired by a FLEXMAP 3D (Luminex).

293 Median fluorescence intensity (MFI) for each isotype/subclass detector was assessed.

294 Background subtraction was conducted, removing background of blank (buffer only)

295 wells. Multiplex assays were repeated twice as two independent experiments.

296

# 297 **RBD-ACE2** binding inhibition multiplex bead-based assay

298 RBD protein was coupled to bioplex beads (Biorad) as described above. 20µl of RBD

299 multiplex bead suspension containing 500 beads per well, 20µl of biotinylated

300 Avitag-ACE2 (kindly provided by Dale Godfrey and Nicholas Gherardin), final

301 concentration of 12.5µg/ml per well, along with 1:100 dilution of each subject's

302 plasma were added to 384 well plates. Plates were covered and incubated at room

303 temperature (RT) whilst shaking for 2 hours, and then washed twice with PBS

304 containing 0.05% Tween20 (PBST). Biotinylated Avitag-ACE2 was detected using

 $40\mu$ l per well of SA-PE at  $4\mu$ g/ml, incubated with shaking for 1 hour at RT.  $10\mu$ l of

306 PE-Biotin amplifier (Thermo Fisher) at 10µg/ml was added and incubated for 1 hour

307 with shaking at RT. Plates were washed and acquired on a FLEXMAP 3D (Luminex).

308 Anti-SARS-CoV-2 RBD neutralising human IgG1 antibody (ACROBiosystems,

309 USA) was included as a positive control, in addition to COVID-19 negative plasma

and buffer only negative controls. The MFI of bound ACE2 was measured after

311 background subtraction of no ACE2 controls. Maximal ACE2 binding MFI was

312 determined by buffer only controls. % ACE2 binding inhibition was calculated as

313 100% - (% ACE2 binding MFI per sample/ Maximal ACE2 binding). RBD-ACE2

314 binding inhibition multiplex assays were repeated independently twice.

315

- 12 -

#### 316 Flow cytometric detection of S- and RBD-specific memory B cells

317	Probes for delineating SARS-CoV-2 S-specific B cells within cryopreserved human
318	PBMC were generated by sequential addition of streptavidin-PE (Thermofisher) to
319	trimeric S protein biotinylated using recombinant Bir-A (Avidity). SARS-CoV-2
320	RBD protein was directly labelled to APC using an APC Conjugation Lightning-link
321	kit (Abcam). Cells were stained with Aqua viability dye (Thermofisher). Monoclonal
322	antibodies for surface staining included: CD19-ECD (J3-119) (Beckman Coulter),
323	CD20 Alexa700 (2H7), IgM-BUV395 (G20-127), CD21-BUV737 (B-ly4), IgD-
324	Cy7PE (IA6-2), IgG-BV786 (G18-145) (BD), CD14-BV510 (M5E2), CD3-BV510
325	(OKT3), CD8a-BV510 (RPA-T8), CD16-BV510 (3G8), CD10-BV510 (HI10a),
326	CD27-BV605 (O323) (Biolegend), IgA-Vio450 (clone) (Miltenyi). Cells were
327	washed, fixed with 1% formaldehyde (Polysciences) and acquired on a BD
328	LSR Fortessa or BD Aria II.

329

# 330 Flow cytometric detection of antigen-specific cTFH, memory CD4+ T cells and

#### 331 memory CD8 T cells

332 Cryopreserved human PBMC were thawed and rested for four hours at 37°C. Cells were cultured in 96-well plates at  $1 \times 10^6$  cells/well and stimulated for 20 hours with 333 2µg/peptide/mL of peptide pools (15mer, overlapping by 11) covering the S1 or S2 334 domains of SARS-CoV-2. Selected donors were also stimulated with SEB (1µg/mL) 335 as a positive control, or individual peptides at 2ug/mL: NCTFEYVSQPFLMDL (S1 336 described in <sup>47</sup>); LPIGINITRFQTLLA (S1 337 epitope: previously epitope): GWTFGAGAALQIPFA (S2 epitope); ALQIPFAMQMAYRFN (S2 epitope); 338 LLQYGSFCTQLNRAL (S2 epitope; <sup>19,47</sup>); QALNTLVKQLSSNFG (S2 epitope). 339 Following stimulation, cells were washed, stained with Live/dead Blue viability dye 340 (ThermoFisher), and a cocktail of monoclonal antibodies: CD27 BUV737 (L128), 341

CD45RA PeCy7 (HI100), CD20 BUV805 (2H7), (BD Biosciences), CD3 BV510
(SK7), CD4 BV605 (RPA-T4), CD8 BV650 (RPA-T8), CD25 APC (BC96), OX-40
PerCP-Cy5.5 (ACT35), CD69 FITC (FN50), CD137 BV421 (4B4-1) (Biolegend),
and CXCR5 PE (MU5UBEE, ThermoFisher). Cells were washed, fixed with 1%
formaldehyde and acquired on a BD LSR Fortessa using BD FACS Diva.

347

348 Mass spectrometry (MS)-based quantitative proteomics of serum anti-S1 349 antibodies. The workflow for anti-S1 proteomic profiling is shown in Extended Data 350 Figure 4A. Briefly, antibodies against SARS-CoV-2 S1 spike protein were affinity-351 purified from convalescent plasma of COVID-19 subjects at different time points 352 using S1 protein-coupled magnetic beads (Acrobiosystems). IgG heavy chains were 353 isolated after reduced SDS-PAGE and digested with trypsin and chymotrypsin to 354 generate peptides for LC-MS/MS using a Thermo Scientific Orbitrap Exploris 480 mass spectrometer coupled to an Ultimate 3000 UHPLC (Dionex). De novo 355 356 sequencing data analysis was performed by Peaks studio X-plus software 357 (Bioinformatics Solution). Peptide sequences were referenced against recovered 358 heavy chain immunoglobulin sequences generated from single sorted S-specific 359 memory B cells<sup>19</sup> to identify matched CDR-H3 peptides. Anti-S1 clonotypic antibody 360 expression levels were monitored by parallel reaction monitoring (PRM) as described 361 previously<sup>28,48</sup>. Fragment ion extracted ion chromatograms (XICs) per CDR-H3 362 peptide were visualized in Skyline version 20.1.0.155 (University of Washington) and 363 inspected manually to ensure correct assignments. The annotated spectra of 364 individual peptides and their corresponding XICs are shown in Supplementary 365 Information.

366

- 14 -

#### 367 Estimating the decay rates

We sought to predict the response variable (y<sub>ij</sub> for patient i at timepoint j) as a function of days post symptom onset, assay replicate (as a binary categorical variable) and a random effect for each individual (both in in intercept and slope). The dependency of the response variables on days post symptom onset can be modelled by using one or two decay slopes. The model can be written as below:

373  $y_{ij} = \beta_0 + b_{0i} + \beta_1 R_{ij} + \beta_2 t_{ij} + b_{2i} t_{ij}$  - for a model with a single slope; and

374  $y_{ij} = \beta_0 + b_{0i} + \beta_1 R_{ij} + \beta_2 t_{ij} + b_{2i} t_{ij} + \beta_3 s_{ij} + b_{3i} s_{ij}$  - for a model with two

375 different slopes, in which:

376 
$$s_{ij} = \begin{cases} 0, t_{ij} < T_0 \\ t_{ij} - T_0, t_{ij} \ge T_0 \end{cases}$$

The parameter  $\beta_0$  is a constant (intercept), and  $b_{0i}$  is a patient-specific adjustment to the overall intercept. The slope parameter  $\beta_2$  is a fixed effect to capture the decay slope before  $T_0$ ; which also has a subject-specific random effect  $b_{2i}$ . To fit a model with two different decay rates, an extra parameter  $\beta_3$  (with a subject-specific random effect  $b_{3i}$ ) was added to represent the difference between the two slopes. Assay variability between replicates was modelled as a single fixed effect  $\beta_1$ , in which we coded the replicate as a binary categorical variable  $R_{ij}$ .

The response variables obtained were highly variable, containing zeros where the value was below the limit of detection and contrasted with samples where very high levels were observed. Thus, we performed log transformations of the non-zero data to help normalize variability and censored every value less than 40 for the microneutralisation data; every value less than 0.01 for the T cell and B cell data; and every negative value for the multiplex data. More specifically, a mixed-effect regression method that allows for censoring at the limit of detection was used to

391 estimate the parameters in the model. This was done by using *lmec* library in *R*, using 392 the ML algorithm to fit for the fixed effects<sup>49</sup>. We also tested if the decay of 393 serological response variables was fitted better by a single or two different decay 394 slopes (likelihood ratio test – based on the likelihood value and the difference in the 395 number of parameters). 95% CI for the fixed effect parameters was calculated based 396 on the standard error estimates, which can be obtained directly by using the *varFix* 397 function from *lmec* library. These analyses were carried out in *R* version 4.0.2.

398

#### 399 Simulating the decay of serological neutralisation activity

400 To understand the decay in serum neutralisation we employed a simulation approach 401 using the parameters estimated from our mixed-effect censoring regression model of 402 decay. The fixed effect estimates averaged the intercept across experimental replicates 403  $(\beta_0 + \beta_{1/2})$  from equations above) and random effects were randomly selected from a 404 multivariate normal distribution with covariance matrix taken from the mixed-effect 405 regression with censoring lmec object. The residual error standard deviation for 406 simulated data every 10 days was taken from the lmec object. The confidence interval 407 for the percentage of subjects with a neutralisation titre above 1:40 was estimated 408 empirically with the percentile method by repeating the simulation 1000 times, where 409 for each replicate the fixed effects were drawn from a normal distribution based on 410 their standard error (as well as randomly selected random effects). To estimate the 411 fold increase in initial neutralisation titre required to achieve >50% of individuals 412 with a titre above 40 at 1 year we assumed that the rate of decay was constant from 413 day 70 onwards and projected forward the expected titres in the simulated populations. The median and confidence intervals for the proportion of individuals 414 415 with titre > 40 were calculated from these 1000 simulated populations.

- 16 -

#### 416 Statistical Analyses

Associations between neutralisation, inhibition of ACE2 binding and antibody 417 418 binding were assessed using both Spearman correlation, and multiple regression (R 419 version 4.0.2). The geometric mean of replicate neutralisation measurements and the 420 arithmetic mean of replicate measurements in other assays were used in the 421 correlation and regression analyses for other measurements. Neutralisation titres 422 below the limit of detection (a titre of 20) were assigned the arbitrary value 10 prior to 423 calculating the geometric mean for the purposes of the Spearman correlation, where 424 rank and not magnitude of the measurements is important. For the multiple regression 425 analysis values below the limit of detection were set at the detection threshold and 426 censoring regression was performed using the function *censReg* (from the *censReg* 427 library<sup>50</sup>) to determine which measurements during early convalescence were 428 significant predictors of neutralisation titre during late convalescence. Comparison of 429 B and T cell frequencies at first and final sampling was performed using Wilcoxon 430 Rank Sum test in GraphPad Prism 8. All statistical tests used were two sided.

#### 431 **Competing interests**

- 432 The authors declare no competing interests.
- 433 Data Availability
- 434 All data are available from the corresponding author upon reasonable request.

### 435 Code Availability

436 All data analysis code can be made available on request.

### 437 Authors' contributions

- 438 A.K.W, J.A.J., J.J.W, H.-X.T., T.E.S., D.L.G., D.S.K., D.C., T.P.G, A.W.C., M.P.D.,
- 439 and S.J.K. designed the study and experiments. A.K.W., J.A.J., J.J.W., K.J.S, A.R.,
- 440 H.-X.T., W.S.L., K.M.W., H.G.K., R.E., S.K.D, H.E.K, F.L.M., T.E.S., and K.S.
- 441 performed experiments. A.K.W., J.A.J., J.J.W, H.-X.T., W.S.L., A.R., D.S.K., T.E.S.,

D.C., K.S., M.P.D., S.J.K. analysed the experimental data. A.K.W, J.A.J., J.J.W,
K.J.S, T.E.S., D.S.K., D.C., M.P.D., and S.J.K. wrote the manuscript. All authors
reviewed the manuscript.

445

#### 446 Acknowledgements

We thank the generous participation of the trial subjects for providing samples. We 447 448 thank E. Haycroft, E. Lopez, C. Nelson and T. Amarasena and C. Batten (University 449 of Melbourne) for excellent technical assistance. The SARS-CoV-2 RBD expression 450 plasmids were kindly provided by F. Krammer (Icahn School of Medicine at Mt 451 Sinai). Recombinant human ACE2 was kindly provided by N. Gherardin and D. 452 Godfrey (University of Melbourne). We acknowledge the Melbourne Cytometry 453 Platform (Melbourne Brain Centre node) for provision of flow cytometry services. 454 We thank T. Chataway and A. Colella (Flinders Proteomics Facility) for technical 455 support with quantitative proteomics. This study was supported by the Victorian 456 Government, an Australian government Medical Research Future Fund award 457 GNT2002073 (SJK, MPD, and AKW), the ARC Centre of Excellence in Convergent 458 Bio-Nano Science and Technology (SJK), an NHMRC program grant APP1149990 459 (SJK and MPD), NHMRC project grant GNT1162760 (AKW), an NHMRC-EU 460 collaborative award APP1115828 (SJK and MPD), the European Union Horizon 2020 461 Research and Innovation Programme under grant agreement 681137 (SJK), Emergent 462 Ventures Fast Grants (AWC), the Jack Ma Foundation (KS) and the A2 Milk 463 Company (KS). JAJ, DSK, and SJK are supported by NHMRC fellowships. JJW is 464 supported by Flinders University DVCR Fellowship and Flinders Health & Medical 465 Research Institute COVID-19 Research Grant. AKW, KS, DC and MPD are 466 supported by NHMRC Investigator grants. The Melbourne WHO Collaborating

- 18 -

- 467 Centre for Reference and Research on Influenza is supported by the Australian
- 468 Government Department of Health.

469

# 470 Figure 1 – Dynamics of serological responses to SARS-CoV-2

471 (A) Timeline of sample collection for each cohort participant (n=64 participants, 158 472 total samples). Samples included only in serological analysis are indicated in black 473 (n=33); samples included in both serological and cellular immune analysis are 474 indicated in red (n=31). Shaded areas indicate early (<50 days) and late (>100 days) 475 convalescent time periods, and dashed line indicates day 70 midpoint. (B) 476 Longitudinal microneutralisation endpoint titre and (C) inhibition of ACE2 binding 477 (%) for individuals. Best fit two-phase decay slope (red line) is indicated. (D) 478 Individual kinetics and best fit decay slopes for IgG binding to spike (S), IgG binding 479 to nucleoprotein (N), IgM binding to S and IgA1 binding to S. (E) Estimated half-life 480 and confidence intervals of the neutralising antibody titre before day70 (red) and after 481 day70 post-symptom onset (blue) are indicated as dashed vertical lines. Estimated 482 early decay rates and confidence intervals for serological inhibition of ACE2 and 483 antibody binding titres are indicated (single phase decay is shown in grey, two phase 484 decay indicated in red/blue).

485

### 486 Figure 2 - Quantification of S-specific memory B cell responses.

- 487 (A) Staining class-switched B cells (CD19+IgD-) with SARS-CoV-2 spike probes
- 488 allows the tracking of antigen-specific cells in subjects previously infected with
- 489 SARS-CoV-2. (B) Frequencies of S-specific IgG+, IgA+ or IgM+ memory B cells as
- 490 a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed
- 491 longitudinally (n=31 subjects). (C) Comparison of S-specific IgG+, IgA+ or IgM+
- 492 memory B cell frequencies at the earliest and latest timepoint available for each
- 493 individual (n=31). Statistics assessed by two-tailed Wilcoxon test.
- 494

#### 495 Figure 3 - Quantification of antigen-specific CD4+ and CD8+ T cell responses.

- 496 (A) Representative staining of AIM markers (CD25, OX-40) on CD4+ Tmem cells
- 497 (CD3+CD4+CD8-CD45RA-CXCR5-) after stimulation with vehicle, S1 or S2 peptide
- 498 pools in longitudinal samples from 1 participant (top row, day 33; middle row, day
- 499 61; bottom row, day 143). (B) Representative staining of AIM markers (CD69,
- 500 CD137) on CD8+ Tmem cells (CD3+CD8+CD4-non-naïve) in longitudinal samples
- from 1 participant (top row, day 41; middle row, day 85; bottom row, day 120). (C)
- 502 Longitudinal changes in the frequency of total S (S1+S2 pool responses after
- 503 background subtraction)-specific responses among cTFH, CD4+ and CD8+ Tmem
- 504 subsets (n=31). (**D**) Comparison of S-specific T cell responses at the earliest and latest
- 505 timepoint available for each individual (n=31). Statistics assessed by two-tailed

506 Wilcoxon test.

507

#### 508 Figure 4 – Modelling of concomitant immune responses after COVID-19

509 (A) Rates of decay of serological neutralisation activity, ACE2 binding inhibition, and

510 S-specific IgG, IgM and IgA following recovery from SAR-CoV-2 infection. (B)

511 Fitted Growth and decay rates for S-specific memory T cell and B cell frequencies in

512 PBMC. (C) Simulation of elicitation and decay of serological neutralisation activity in

- 513 1000 individuals based on distributions observed in our SARS-CoV-2 convalescent
- 514 cohort. The simulation was repeated 1000 times to estimate the proportion of
- 515 individuals maintaining a neutralisation titre above 1:40 across multiple simulations

516 (median and 95% confidence intervals shown in red).

517

# 518 Extended data figure 1. Demographic and clinical characteristics of the

519 convalescent COVID-19 cohort.

_	$\mathbf{a}$	0
~	• •	11
,	1.	1,
~	_	~

#### 521 Extended data figure 2: Fitting of the decline in antibody binding across

# 522 different immunoglobulin isotypes.

- 523 The best-fit model and half-lives are shown for the fitting of the decay of antibody
- 524 binding to different SARS-CoV-2 antigens (n=64 subjects). Two-phase decay is
- 525 indicated by red (before day 70) and blue (after day 70) shaded areas. No shading
- 526 indicates where single-phase decay provided the best fit.

527

### 528 Extended Data Figure 3: Correlation of antibody binding and ACE2 inhibition

# 529 with neutralisation.

530 A heat-map of Spearman correlations between neutralisation titre and the serological

531 measurements of antibody binding (by isotype and antigen). Correlations were

assessed in early ( $\leq$ 50 days, left column n=54 subjects) and late ( $\geq$ 100 days, right

533 middle column, n=47 subjects) convalescence in all subjects were data was available.

- 534 The association between early antibody binding and late neutralisation is also shown
- 535 (right column, n=47 subjects). All correlations are Spearman correlations.  $*P \le 0.05$ ,

536 \*\*P≤0.01, \*\*\*P≤0.001.

537

#### 538 Extended Data Figure 4: MS-based quantification of immunoprecipitated S1-

# 539 specific clonotypic antibodies.

540 (A) Combined B cell receptor sequencing and proteomics platform enables

541 identification and quantification of circulating anti-S1 antibodies. S1-specific IgG was

- 542 purified from plasma of SARS-CoV-2 convalescent subjects using antigen-coupled
- 543 magnetic beads and heavy chains subject to LC-MC/MS. Peptide spectra are searched

544	against B-cell receptor sequencers recovered from single sorted S-specific memory B
545	cells from the same individuals to identify clonotypes based upon CDR-H3 amino
546	acid sequence. Clonotype specific peptides are then used as barcodes for relative
547	quantitative parallel reaction monitoring (PRM) for tracking in longitudinal plasma
548	samples. Targeted peptides are monitored during elution from HPLC and individual
549	peptides quantified based on abundance chromatography curves. (B) Clonotypes
550	identified based on matched CDR-H3 sequences from S1-specific plasma IgG and B
551	cell receptor sequences from SARS-CoV-2 convalescent subjects (n=4). (C)
552	Longitudinal changes in the relative plasma abundance of anti-S1 clonotypes within
553	four convalescent subjects over time. The quantity of each reference peptide is
554	expressed as area under the curve (AUC) derived from extracted ion chromatography.
555	
555 556	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells.
555 556 557	<b>Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells.</b> (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+
555 556 557 558	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+
555 556 557 558 559	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-)
<ul> <li>555</li> <li>556</li> <li>557</li> <li>558</li> <li>559</li> <li>560</li> </ul>	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31
555 556 557 558 559 560 561	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects).
<ul> <li>555</li> <li>556</li> <li>557</li> <li>558</li> <li>559</li> <li>560</li> <li>561</li> <li>562</li> </ul>	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects).
<ul> <li>555</li> <li>556</li> <li>557</li> <li>558</li> <li>559</li> <li>560</li> <li>561</li> <li>562</li> <li>563</li> </ul>	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects). Extended Data Figure 6: RBD-specific memory B cell dynamics.
555 556 557 558 559 560 561 562 563 564	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects). Extended Data Figure 6: RBD-specific memory B cell dynamics. (A) Frequencies of RBD-specific IgG+, IgA+ or IgM+ memory B cells as a
555 556 557 558 559 560 561 562 563 564 565	Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells. (A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+ CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects). Extended Data Figure 6: RBD-specific memory B cell dynamics. (A) Frequencies of RBD-specific IgG+, IgA+ or IgM+ memory B cells as a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed

- 567 frequencies at the earliest and latest timepoint available for each individual (n=31).
- 568 Statistics assessed by two-tailed Wilcoxon test.

569	
570	Extended Data Figure 7: Fitting of the kinetics of S- and RBD-specific memory B
571	cell responses over time.
572	The best-fit half-lives are shown for the fitting of the growth and/or decay of S- or
573	RBD-specific memory B cells (n=31 subjects). Two-phase decay is indicated by red
574	(before day 70) and blue (after day 70) shaded areas. No shading indicates where a
575	single-phase decay model was used to fit the data.
576	
577	Extended Data Figure 8: Fitting of the decline in SARS-CoV-2-specific T cells
578	over time.
579	The best-fit half-lives are shown for the fitting of the decay of cTFH, CD4+ Tmem
580	and CD8+ Tmem specific to total S (S1+S2 responses combined), S1 or S2 peptide
581	pools (n=31 subjects). In all cases decay was fit with a single-phase decay model with
582	the half-lives shown.
583	
584	Extended Data Figure 9: S1 and S2-specific CD4+ T cell responses.
585	(A, C) Representative staining of AIM markers following S1 and S2 peptide pool
586	stimulation among (A) cTFH (CD3+CD4+CD8-CD45RA-CXCR5+) or (C) CD4+
587	Tmem cells and longitudinal cohort analysis (n=31). ( <b>B</b> , <b>D</b> ) Comparison of S1 or S2-
588	specific (B) cTFH or (D) CD4+ Tmem responses at the earliest and latest visit for
589	each participant, as well as paired frequency of S1 versus S2 responses at the initial or
590	final visit (n=31). Statistics assessed by two-tailed Wilcoxon test.
591	

592 Extended Data Figure 10: Epitope-specific CD4+ T cell responses.

- 593 (A) Representative staining of AIM markers following S1 or S2 peptide pool or
- 594 individual peptide stimulation among the CD4+ Tmem population. (**B**,**C**)
- 595 Longitudinal peptide-specific frequencies in individual subjects (n=9; solid line,
- 596 CD4+ Tmem; dashed line, cTFH) for whom (B) multiple or (C) single epitopes were
- 597 identified.

<ol> <li>Deng, W., et al. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science (New York, N.Y) 369, 818-823 (2020).</li> <li>Chandrashckar, A., et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science (New York, N.Y) 369, 812-817 (2020).</li> <li>To, K.K., et al. COVID-19 re-infection by a phylogenetically distinct SARS- coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. The New England journal of medicine 357, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Coronavirus protective immunity is short-lasting. medRxiv, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mid Covid-19. The New England journal of medicine (2020).</li> <li>Crawford, K.H., et al. Opnamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv, 2020.2008.2006.2016/9367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20165553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinctics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functio</li></ol>	598	References				
<ul> <li>in rhesus macaques. <i>Science (New York, N.Y.)</i> 369, 818-823 (2020).</li> <li>Chandrashckar, A., et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <i>Science (New York, N.Y.)</i> 369, 812-817 (2020).</li> <li>To, K.K., et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. <i>Clinical infections diseases : an official publication of the Infectious Diseases Society of America</i> (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccinc antigens. <i>The New England journal of medicine</i> 357, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Robbiani, D.F., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2, et al. Neutralizing antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2003.2006.2016/05367 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kiters of COVID-19 patients. <i>medRxiv</i>, 2020.2007.2018.2015/01605367 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2018.2015/9178 (2020).</li> <li>Beaudoin-Bussières, <i>G. et al.</i> Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20142492 (2020).</li> <li>Rodda, L.B., et al. Lon</li></ul>	599	1.	Deng, W., et al. Primary exposure to SARS-CoV-2 protects against reinfection			
<ol> <li>Chandrashekar, A., et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science (New York, N.Y.) 369, 812-817 (2020).</li> <li>To, K.K., et al. COVID-19 re-infection by a phylogenetically distinct SARS- coronavirus-2 strain confirmed by whole genome sequencing. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. The New England journal of medicine 357, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Coronavirus protective immunity is short-lasting. medRxiv, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature (2020).</li> <li>Barrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in persons with Mild Covid-19. The New England journal of medicine (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.2015610 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2015.9178 (2020).</li> <li>Rodda, L.B., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2008.2005.2016/192 (2</li></ol>	600		in rhesus macaques. Science (New York, N.Y.) 369, 818-823 (2020).			
<ul> <li>in rhesus macaques. <i>Science (New York, N.Y.)</i> 369, 812-817 (2020).</li> <li>To, K.K., <i>et al.</i> COVID-19 re-infection by a phylogenetically distinct SARS-correatives-2 strain confirmed by whole genome sequencing. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. <i>The New England journal of medicine</i> 357, 1903-1915 (2007).</li> <li>Edridge, A.W., <i>et al.</i> Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Ibarrondo, F.J., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Sho, B., <i>et al.</i> Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.2015.2015.2015.2015.2015.2015.2015.2015</li></ul>	601	2.	Chandrashekar, A., et al. SARS-CoV-2 infection protects against rechallenge			
<ol> <li>To, K.K., et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. <i>The New England journal of medicine</i> <b>357</b>, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.2016/9367 (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Jsho, B., et al. Mucuralizing and binding antibody kinetics of COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2019.120159178 (2020).</li> <li>Rodda, L.B., et al. SARS-CoV-2 infection induces nobust, neutralizing antibody responses in a SARS-CoV-2 infection induces nobust, neutralist medRxiv, 2020.2007.2019.14839 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2.specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2019.104639 (2020).</li> <li>Rodda, L.B., et al. Congitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2019.20148429 (2020).</li> <li>Muecksch, F., et al. Congi</li></ol>	602		in rhesus macaques, <i>Science (New York, N.Y.)</i> <b>369</b> , 812-817 (2020).			
<ul> <li>coronavirus-2 strain confirmed by whole genome sequencing. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. <i>The New England journal of medicine</i> <b>357</b>, 1903-1915 (2007).</li> <li>Edridge, A.W., <i>et al.</i> Coronavirus protective immunity is short-lasting <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Sho, B., <i>et al.</i> Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.2016553 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.2016553 (2020).</li> <li>Wu, J., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2012.10159178 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Longitudinal valuation and decline of antibody responses in SARS-CoV-2 infection induces robust, neutralizing antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2007.2019.20151126 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>B</li></ul>	603	3.	To, K.K., <i>et al.</i> COVID-19 re-infection by a phylogenetically distinct SARS-			
<ul> <li>infectious diseases : an official publication of the Infectious Diseases Society of America (2020).</li> <li>Amanan, LJ., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccinc antigens. The New England journal of medicine 357, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. The New England journal of medicine (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Muecksch, F., et al. Analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2005.2016.2008.2016 (2020).</li> <librochot, al.="" analys<="" e.,="" et="" td=""><td>604</td><td>0.</td><td>coronavirus-2 strain confirmed by whole genome sequencing. <i>Clinical</i></td></librochot,></ul>	604	0.	coronavirus-2 strain confirmed by whole genome sequencing. <i>Clinical</i>			
<ul> <li><i>of America</i> (2020).</li> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. <i>The New England journal of medicine</i> <b>357</b>, 1903-1915 (2007).</li> <li>Edridge, A.W., <i>et al.</i> Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Ibarrondo, F.J., <i>et al.</i> Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., <i>et al.</i> Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2011.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2. specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.20148429 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.20148429 (2020).</li> <li>Seow, J. <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, F., <i>et al.</i> Analysis of SARS</li></ul>	605		infectious diseases · an official publication of the Infectious Diseases Society			
<ol> <li>Amanna, I.J., Carlson, N.E. &amp; Slifka, M.K. Duration of humoral immunity to common viral and vaccine antigens. <i>The New England journal of medicine</i> <b>357</b>, 1903-1915 (2007).</li> <li>Edridge, A.W., <i>et al.</i> Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Ibarrondo, F.J., <i>et al.</i> Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Scawford, K.H., <i>et al.</i> Nucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194635 (2020).</li> <li>Kodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.201218429 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2019.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and n</li></ol>	606		of America (2020).			
<ul> <li>common viral and vaccine antigens. <i>The New England journal of medicine</i> 357, 1903-1915 (2007).</li> <li>Edridge, A.W., <i>et al.</i> Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., <i>et al.</i> Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Barrondo, F.J., <i>et al.</i> Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., <i>et al.</i> Neusal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.2007.2018.20156810 (2020).</li> <li>Yuo, XY., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2019.179178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2019.2048429 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Muceksch, F., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodie</li></ul>	607	4	Amanna LI Carlson NE & Slifka MK Duration of humoral immunity to			
<ul> <li>357, 1903-1915 (2007).</li> <li>Edridge, A.W., et al. Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Schard, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Isho, B., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.20148429 (2020).</li> <li>Muecksch, F., et al. Longitudinal enalysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux,</li></ul>	608		common viral and vaccine antigens. The New England journal of medicine			
<ul> <li>Edridge, A.W., et al. Coronavirus protective immunity is short-lasting. <i>medRxiv</i>, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2012.120159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.2014639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2.specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Kacks-CoV-2 infection <i>medRxiv</i>, 2020.2007.20148429 (2020).</li> <li>Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 infaction and asymptomatic carriers. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot</li></ul>	609		<b>357</b> 1903-1915 (2007)			
<ul> <li>medRxiv, 2020.2005.2011.20086439 (2020).</li> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Robbiani, D.F., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England Journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Sho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2012.0159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS-CoV-2 spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2001.20171843 (2020).</li> <li>Scow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection induces subst, neutralizing antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2019.194639 (2020).</li> <li>Mucksch, F., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibody responses in SARS-CoV-2 infection induces robust, neutralizing antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2019.194639 (2020).</li> <li>Mucksch, F., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizin</li></ul>	610	5	Edridge AW <i>et al</i> Coronavirus protective immunity is short-lasting			
<ul> <li>Robbiani, D.F., et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> (2020).</li> <li>Robbiani, D.F., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.2016553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2018/2012.001.9148429 (2020).</li> <li>Kodda, L.B., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Berochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Imm</i></li></ul>	611	5.	medRriv 2020 2005 2011 20086439 (2020)			
<ol> <li>convales.cent individuals. Nature (2020).</li> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.20148429 (2020).</li> <li>Wuecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SAR</li></ol>	612	6	Robbiani DF et al Convergent antibody responses to SARS-CoV-2 in			
<ol> <li>Ibarrondo, F.J., et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. The New England journal of medicine (2020).</li> <li>Crawford, K.H., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., et al. Anogitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2007.2014.2015112</li></ol>	613	0.	convalescent individuals <i>Nature</i> (2020)			
<ol> <li>Persons with Mild Covid-19. <i>The New England journal of medicine</i> (2020).</li> <li>Crawford, K.H., <i>et al.</i> Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., <i>et al.</i> Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. <i>medRxiv</i>, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (202</li></ol>	614	7	Ibarrando E L at al Banid Decay of Anti-SARS-CoV-2 Antibodies in			
<ul> <li>Crawford, K.I., et al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. medRxiv, 2020.2008.2006.20169367 (2020).</li> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2005.2012.2005.2012.20098236 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>Brochot, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>Juno, J.</li></ul>	615	1.	Persons with Mild Covid-19 The New England journal of medicine (2020)			
<ul> <li>6.17 of averset, et al. bytannes of neuralizing analysis of the intermediation of the intermediatin o</li></ul>	616	8	Crawford K H <i>et al</i> Dynamics of neutralizing antibody titers in the months			
<ol> <li>Isho, B., et al. Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Muceksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2007.2015.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>Brochot, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature medicine (2020).</li> </ol>	617	0.	after SARS-CoV-2 infection <i>medRriv</i> 2020 2008 2006 20169367 (2020)			
<ol> <li>J. Halo, D., et al. Wilcoal versions system antibody caponics of SrRS-CoV-2 antigens in COVID-19 patients. medRxiv, 2020.2008.2001.20166553 (2020).</li> <li>Yao, XY., et al. Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature medicine (2020).</li> </ol>	618	0	Isho B at al Mucosal versus systemic antibody responses to $SARS-CoV-2$			
<ol> <li>Yao, XY., <i>et al.</i> Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. <i>medRxiv</i>, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., <i>et al.</i> SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ol>	610	).	antigens in COVID-19 nations. $mod Rriv 2020, 2008, 2001, 20166553, (2020)$			
<ol> <li>Fao, AF., et al. Neutraling and ontaing antibody kinetics of COVID-19.</li> <li>patients during hospital and convalescent phases. medRxiv, 2020.2007.2018.20156810 (2020).</li> <li>Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. bioRxiv, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. medRxiv, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature medicine (2020).</li> </ol>	620	10	Vao X-V <i>et al.</i> Neutralizing and hinding antibody kinetics of COVID-19			
<ul> <li>2020.2007.2018.20156810 (2020).</li> <li>11. Wu, J., et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>12. Beaudoin-Bussières, G., et al. Decline of humoral responses against SARS- CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>13. Rodda, L.B., et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>14. Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>15. Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	621	10.	nation shows a second and second			
<ol> <li>Hubberger (2020)</li> <li>Hubberger (2020)</li></ol>	622		$2020\ 2007\ 2018\ 20156810\ (2020)$			
<ul> <li>Wu, y., et al. DARS COV 2 Infection induces stating a national infinite responses in convalescent patients following symptomatic COVID-19. <i>medRxiv</i>, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS-COV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	623	11	Wu I et al SARS-CoV-2 infection induces sustained humoral immune			
<ul> <li>medRxiv, 2020.2007.2021.20159178 (2020).</li> <li>Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	623	11.	responses in convalescent nations following symptomatic COVID-19			
<ol> <li>12. Beaudoin, <i>Bobilion Bobilion (2020)</i>.</li> <li>13. Beaudoin-Bussières, G., <i>et al.</i> Decline of humoral responses against SARS-CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>13. Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>14. Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>15. Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ol>	625		medRriv 2020 2007 2021 20159178 (2020)			
<ul> <li>CoV-2 Spike in convalescent individuals. <i>bioRxiv</i>, 2020.2007.2009.194639 (2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	626	12	Beaudoin-Bussières <i>G</i> et al Decline of humoral responses against SARS-			
<ul> <li>(2020).</li> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	627	121	CoV-2 Spike in convalescent individuals <i>bioRxiv</i> 2020 2007 2009 194639			
<ol> <li>Rodda, L.B., <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ol>	628		(2020)			
<ul> <li>after mild COVID-19. <i>medRxiv</i>, 2020.2008.2011.20171843 (2020).</li> <li>14. Seow, J., <i>et al.</i> Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>15. Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> <b>53</b>, 98-105.e105 (2020).</li> <li>19. Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	629	13.	Rodda, L.B. <i>et al.</i> Functional SARS-CoV-2-specific immune memory persists			
<ul> <li>and think cover all 10. metaletty, 2020/2001/2011/2011/010 (2020).</li> <li>14. Seow, J., et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv, 2020.2007.2009.20148429 (2020).</li> <li>15. Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. medRxiv, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature medicine (2020).</li> </ul>	630	101	after mild COVID-19 <i>medRxiv</i> 2020 2008 2011 20171843 (2020)			
<ul> <li>SARS-CoV-2 infection. <i>medRxiv</i>, 2020.2007.2009.20148429 (2020).</li> <li>Muecksch, F., <i>et al.</i> Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	631	14.	Seow, J. et al. Longitudinal evaluation and decline of antibody responses in			
<ul> <li>billie Cov 2 infection methality, 2020/2007/2014/2014/2015/(2020).</li> <li>Muecksch, F., et al. Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	632	1.11	SARS-CoV-2 infection <i>medRxiv</i> 2020 2007 2009 20148429 (2020)			
<ul> <li>hadeeksen, F., et al. Eoligitatinal analysis of conteal scrology assay</li> <li>performance and neutralising antibody levels in COVID19 convalescents. <i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	633	15	Muecksch F <i>et al</i> Longitudinal analysis of clinical serology assay			
<ul> <li><i>medRxiv</i>, 2020.2008.2005.20169128 (2020).</li> <li>16. Wajnberg, A., <i>et al.</i> SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	634	10.	performance and neutralising antibody levels in COVID19 convalescents			
<ul> <li>16. Wajnberg, A., et al. SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv, 2020.2007.2014.20151126 (2020).</li> <li>17. Brochot, E., et al. Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. medRxiv, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature medicine (2020).</li> </ul>	635		<i>medRxiv</i> 2020.2008.2005.20169128 (2020).			
<ul> <li>antibolig, 11, et al. billib cov 2 infection induces robust, neutralizing antibody responses that are stable for at least three months. <i>medRxiv</i>, 2020.2007.2014.20151126 (2020).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	636	16	Wainberg A <i>et al</i> SARS-CoV-2 infection induces robust neutralizing			
<ul> <li>antiooly responses that are share for a feast three months, meanance (2020,2007,2014,20151126 (2020)).</li> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020,2005,2012,20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	637	10.	antibody responses that are stable for at least three months. <i>medRxiv</i> .			
<ul> <li>Brochot, E., <i>et al.</i> Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>, 2020.2005.2012.20098236 (2020).</li> <li>Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	638		2020 2007 2014 20151126 (2020)			
<ul> <li>640 SARS-CoV-2 inpatients and asymptomatic carriers. <i>medRxiv</i>,</li> <li>641 2020.2005.2012.20098236 (2020).</li> <li>642 18. Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals</li> <li>643 Development of Potent Neutralizing Antibodies with Limited Somatic</li> <li>644 Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>645 19. Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in</li> <li>646 recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	639	17	Brochot E <i>et al</i> Anti-Spike anti-Nucleocansid and neutralizing antibodies in			
<ul> <li>b) 10 b) 11 b) 12 mpatients and asymptomate carriers. <i>meanetry</i>, 2020.2005.2012.20098236 (2020).</li> <li>18. Seydoux, E., <i>et al.</i> Analysis of a SARS-CoV-2-Infected Individual Reveals</li> <li>Development of Potent Neutralizing Antibodies with Limited Somatic</li> <li>Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>19. Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in</li> <li>recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	640	17.	SARS-CoV-2 inpatients and asymptomatic carriers <i>medRriv</i>			
<ul> <li>18. Seydoux, E., et al. Analysis of a SARS-CoV-2-Infected Individual Reveals</li> <li>bevelopment of Potent Neutralizing Antibodies with Limited Somatic</li> <li>Mutation. Immunity 53, 98-105.e105 (2020).</li> <li>Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in</li> <li>recovered patients with COVID-19. Nature medicine (2020).</li> </ul>	641		2020.2005.2012.20098236 (2020).			
<ul> <li>b) 10. Beyldean, D., et al. Humpslib of a Britts Cov D Infected Individual Reveal</li> <li>b) 10. Development of Potent Neutralizing Antibodies with Limited Somatic</li> <li>b) 10. Immunity 53, 98-105.e105 (2020).</li> <li>b) 10. Juno, J.A., et al. Humoral and circulating follicular helper T cell responses in</li> <li>b) 10. recovered patients with COVID-19. Nature medicine (2020).</li> </ul>	642	18	Sevdoux E <i>et al</i> Analysis of a SARS-CoV-2-Infected Individual Reveals			
<ul> <li>Mutation. <i>Immunity</i> 53, 98-105.e105 (2020).</li> <li>Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. <i>Nature medicine</i> (2020).</li> </ul>	643	10.	Development of Potent Neutralizing Antibodies with Limited Somatic			
<ul> <li>In the second second</li></ul>	644		Mutation. <i>Immunity</i> <b>53</b> , 98-105.e105 (2020).			
646 recovered patients with COVID-19. <i>Nature medicine</i> (2020).	645	19.	Juno, J.A., <i>et al.</i> Humoral and circulating follicular helper T cell responses in			
	646		recovered patients with COVID-19. <i>Nature medicine</i> (2020).			

- 64720.Schulien, I., et al. <em>Ex vivo</em> detection of SARS-CoV-2-specific648CD8+ T cells: rapid induction, prolonged contraction, and formation of649functional memory. bioRxiv, 2020.2008.2013.249433 (2020).
- Neidleman, J., *et al.* SARS-CoV-2-specific T cells exhibit phenotypic features
  of robust helper function, lack of terminal differentiation, and high
  proliferative potential. *Cell Rep Med*, 100081 (2020).
- 653 22. Grifoni, A., *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
  654 Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 181, 1489655 1501.e1415 (2020).
- Braun, J., *et al.* SARS-CoV-2-reactive T cells in healthy donors and patients
  with COVID-19. *Nature* (2020).
- Habel, J.R., *et al.* Suboptimal SARS-CoV-2-specific CD8+ T-cell response
  associated with the prominent HLA-A\*02:01 phenotype. *medRxiv*,
  2020.2008.2017.20176370 (2020).
- 661 25. Selva, K.J., *et al.* Distinct systems serology features in children, elderly and COVID patients. *medRxiv*, 2020.2005.2011.20098459 (2020).
- 663 26. Grandjean, L., *et al.* Humoral Response Dynamics Following Infection with SARS-CoV-2. *medRxiv*, 2020.2007.2016.20155663 (2020).
- Singh, M., *et al.* Lymphoma Driver Mutations in the Pathogenic Evolution of
  an Iconic Human Autoantibody. *Cell* 180, 878-894.e819 (2020).
- 667 28. Wang, J.J., *et al.* Molecular Profiling and Clonal Tracking of Secreted
  668 Rheumatoid Factors in Primary Sjögren's Syndrome. *Arthritis & rheumatology*669 (*Hoboken, N.J.*) 70, 1617-1625 (2018).
- 670 29. Lau, D., *et al.* Low CD21 expression defines a population of recent germinal
  671 center graduates primed for plasma cell differentiation. *Science immunology*672 2(2017).
- 673 30. Davis, C.W., *et al.* Longitudinal Analysis of the Human B Cell Response to
  674 Ebola Virus Infection. *Cell* 177, 1566-1582.e1517 (2019).
- Matsuda, K., *et al.* Prolonged evolution of the memory B cell response
  induced by a replicating adenovirus-influenza H5 vaccine. *Science immunology* 4(2019).
- Wec, A.Z., *et al.* Longitudinal dynamics of the human B cell response to the
  yellow fever 17D vaccine. *Proceedings of the National Academy of Sciences of the United States of America* 117, 6675-6685 (2020).
- 33. Brown, D.M., Dilzer, A.M., Meents, D.L. & Swain, S.L. CD4 T cell-mediated
  protection from lethal influenza: perform and antibody-mediated mechanisms
  give a one-two punch. *Journal of immunology (Baltimore, Md. : 1950)* 177,
  2888-2898 (2006).
- 685 34. Grifoni, A., *et al.* Targets of T Cell Responses to SARS-CoV-2 Coronavirus in
  686 Humans with COVID-19 Disease and Unexposed Individuals. *Cell* (2020).
- 687 35. Weiskopf, D., *et al.* Phenotype and kinetics of SARS-CoV-2-specific T cells
  688 in COVID-19 patients with acute respiratory distress syndrome. *Science*689 *immunology* 5(2020).
- 690 36. Mateus, J., *et al.* Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science (New York, N.Y.)* (2020).
- 692 37. Crotty, S., *et al.* Cutting edge: long-term B cell memory in humans after
  693 smallpox vaccination. *Journal of immunology (Baltimore, Md. : 1950)* 171,
  694 4969-4973 (2003).
- 695 38. Plotkin, S.A. Updates on immunologic correlates of vaccine-induced
  696 protection. *Vaccine* 38, 2250-2257 (2020).

- 697 39. Cox, R.J. Correlates of protection to influenza virus, where do we go from 698 here? *Human vaccines & immunotherapeutics* **9**, 405-408 (2013).
- Keech, C., *et al.* Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike
  Protein Nanoparticle Vaccine. *The New England journal of medicine* (2020).
- Jackson, L.A., *et al.* An mRNA Vaccine against SARS-CoV-2 Preliminary
  Report. *The New England journal of medicine* (2020).
- Caly, L., *et al.* Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. *Med J Aust* 212, 459-462 (2020).
- Houser, K.V., *et al.* Prophylaxis With a Middle East Respiratory Syndrome
  Coronavirus (MERS-CoV)-Specific Human Monoclonal Antibody Protects
  Rabbits From MERS-CoV Infection. *The Journal of infectious diseases* 213, 1557-1561 (2016).
- Subbarao, K., *et al.* Prior infection and passive transfer of neutralizing
  antibody prevent replication of severe acute respiratory syndrome coronavirus
  in the respiratory tract of mice. *Journal of virology* 78, 3572-3577 (2004).
- 714 Methods References:
- Wrapp, D., *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science (New York, N.Y.)* 367, 1260-1263 (2020).
- Amanat, F., *et al.* A serological assay to detect SARS-CoV-2 seroconversion
  in humans. *Nature medicine* (2020).
- Peng, Y., *et al.* Broad and strong memory CD4+ and CD8+ T cells induced by
  SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nature immunology* (2020).
- 48. Wang, J.J., Colella, A.D., Beroukas, D., Chataway, T.K. & Gordon, T.P.
  Precipitating anti-dsDNA peptide repertoires in lupus. *Clinical and experimental immunology* 194, 273-282 (2018).
- Vaida, F. & Liu, L. Fast Implementation for Normal Mixed Effects Models
  With Censored Response. *J Comput Graph Stat* 18, 797-817 (2009).
- 727 50. Henningsen, A. censReg: Censored Regression (Tobit) Models. (2017).
- 728

713



#### Figure 1 – Dynamics of serological responses to SARS-CoV-2

(A) Timeline of sample collection for each cohort participant (n=64 participants, 158 total samples). Samples included only in serological analysis are indicated in black (n=33); samples included in both serological and cellular immune analysis are indicated in red (n=31). Shaded areas indicate early ( $\leq$ 50 days) and late ( $\geq$ 100 days) convalescent time periods, and dashed line indicates day 70 midpoint. (B) Longitudinal microneutralisation endpoint titre and (C) inhibition of RBD-ACE2 binding (%) for individuals. Best fit two-phase decay slope (red line) is indicated. (D) Individual kinetics and best fit decay slopes for IgG binding to spike (S), IgG binding to nucleoprotein (N), IgM binding to S and IgA1 binding to S. (E) Estimated half-life and confidence intervals of the neutralising antibody titre before day70 (red) and after day70 post-symptom onset (blue) are indicated as dashed vertical lines. Estimated early decay rates and confidence intervals for serological inhibition of ACE2 and antibody binding titres are indicated (single phase decay is shown in grey, two phase decay indicated in red/blue).





# Figure 2 - Quantification of S-specific memory B cell responses.

(A) Staining class-switched B cells (CD19+IgD-) with SARS-CoV-2 spike probes allows the tracking of antigen-specific cells in subjects previously infected with SARS-CoV-2. (B) Frequencies of S-specific IgG+, IgA+ or IgM+ memory B cells as a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed longitudinally (n=31 subjects). (C) Comparison of S-specific IgG+, IgA+ or IgM+ memory B cell frequencies at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.



### Figure 3 - Quantification of antigen-specific CD4+ and CD8+ T cell responses.

(A) Representative staining of AIM markers (CD25, OX-40) on CD4+ Tmem cells (CD3+CD4+CD8-CD45RA-CXCR5-) after stimulation with vehicle, S1 or S2 peptide pools in longitudinal samples from 1 participant (top row, day 33; middle row, day 61; bottom row, day 143). (B) Representative staining of AIM markers (CD69, CD137) on CD8+ Tmem cells (CD3+CD8+CD4-non-naïve) in longitudinal samples from 1 participant (top row, day 41; middle row, day 85; bottom row, day 120). (C) Longitudinal changes in the frequency of total S (S1+S2 pool responses after background subtraction)-specific responses among cTFH, CD4+ and CD8+ Tmem subsets (n=31). (D) Comparison of S-specific T cell responses at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.



С



### Figure 4 – Modelling of concomitant immune responses after COVID-19

(A) Rates of decay of serological neutralisation activity, ACE2 binding inhibition, and S-specific IgG, IgM and IgA following recovery from SAR-CoV-2 infection. (B) Fitted Growth and decay rates for S-specific memory T cell and B cell frequencies in PBMC. (C) Simulation of elicitation and decay of serological neutralisation activity in 1000 individuals based on distributions observed in our SARS-CoV-2 convalescent cohort. The simulation was repeated 1000 times to estimate the proportion of individuals maintaining a neutralisation titre above 1:40 across multiple simulations (median and 95% confidence intervals shown in red).

# Extended Data Figures

	Full Cohort	Cellular Analysis Cohort
	(n=64)	(n=31)
Age, median (IQR)	55 (62, 49)	52 (56, 31)
Gender, % female (n)	43.8% (28)	45.2% (14)
Disease severity, % (n) - mild	68.8% (44)	74.2% (23)
- moderate	23.4% (15)	16.1% (5)
- severe	7.8% (5)	9.7% (3)
Positive PCR test, % (n)	84.4% (54)	83.9% (26)

Extended data figure 1. Demographic and clinical characteristics of the convalescent COVID-19 cohort.





# Extended data figure 2: Fitting of the decline in antibody binding across different immunoglobulin isotypes.

The best-fit model and half-lives are shown for the fitting of the decay of antibody binding to different SARS-CoV-2 antigens (n=64 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where single-phase decay provided the best fit.

Neutralisation -	1.00***	1.00***	0.88***
ACE2 binding inhibition	0.73***	0.81***	0.79***
Anti–S IgG –	0.47***	0.55***	0.52***
Anti-S1 lgG —	0.71***	0.84***	0.81***
Anti–S2 IgG –	0.58***	0.60***	0.59***
Anti–RBD IgG –	0.70***	0.78***	0.76***
Anti–N IgG –	0.47***	0.71***	0.47**
Anti–S IgG1 –	0.39**	0.42**	0.47**
Anti-S1 lgG1 —	0.69***	0.83***	0.78***
Anti-S2 lgG1	0.51***	0.53***	0.52***
Anti-RBD IgG1	0.64***	0.76***	0.71***
Anti–N IgG1 —	0.41**	0.68***	0.43**
Anti-S IgG2	-0.06	0.14	-0.11
Anti-S1 lgG2 —	0.23	0.40**	0.29
Anti-S2 lgG2 —	0.08	0.17	0.16
Anti-RBD IgG2 -	0.25	0.47***	0.39*
Anti-N IgG2 -	0.07	0.57***	0.27
Anti–S IgG3 —	0.46***	0.52***	0.55***
Anti-S1 lgG3 —	0.59***	0.68***	0.65***
Anti-S2 lgG3 —	0.44***	0.41**	0.47**
Anti-RBD lgG3 —	0.60***	0.55***	0.57*** 0.5
Anti–N IgG3 —	0.43**	0.61***	0.50** 0.0
Anti–S IgG4 —	0.17	0.38*	0.20 -0.5
Anti-S1 lgG4 —	0.20	0.29	0.04 -1.0
Anti-S2 lgG4 —	0.18	0.20	0.03
Anti-RBD IgG4	0.01	0.03	-0.14
Anti–N IgG4 –	0.08	0.63***	0.10
Anti–S IgM —	0.45***	0.51***	0.52***
Anti–S1 lgM —	0.61***	0.68***	0.69***
Anti–S2 IgM –	0.18	0.05	0.28
Anti-RBD IgM -	0.56***	0.47***	0.64***
Anti–N IgM	-0.04	-0.14	-0.03
Anti-S IgA1	0.29*	0.18	0.09
Anti-S1 lgA1 —	0.36**	0.44**	0.25
Anti–S2 lgA1 —	0.35**	0.27	0.25
Anti-RBD IgA1 -	0.30*	0.39**	0.22
Anti–N IgA1	0.31*	0.07	0.31
Anti–S IgA2	0.32*	0.32*	0.14
Anti–S1 lgA2 —	0.40**	0.57***	0.33*
Anti–S2 IgA2	0.45***	0.44**	0.37*
Anti-RBD IgA2	0.40**	0.51***	0.29
Anti–N IgA2	0.39**	0.30*	0.37*
	Early	Late	Early level vs. late neutralisation

# Correlation with neutralisation

# **Extended Data Figure 3: Correlation of antibody binding and ACE2 inhibition with** neutralisation.

A heat-map of Spearman correlations between neutralisation titre and the serological measurements of antibody binding (by isotype and antigen). Correlations were assessed in early ( $\leq$ 50 days, left column n=54 subjects) and late ( $\geq$ 100 days, right middle column, n=47 subjects) convalescence in all subjects were data was available. The association between early antibody binding and late neutralisation is also shown (right column, n=47 subjects). All correlations are Spearman correlations. \*P $\leq$ 0.05, \*\*P $\leq$ 0.01, \*\*\*P $\leq$ 0.001.



В

Subject	IGHV	IGHD	IGHJ	Translated CDR-H3 sequences	Matched CDR-H3 peptide sequences
CP04	1-3	3-10	6	ARILGTTRKYFDDSERDGMDVW	KYFDDSERDGMDVWGQGTTVTVSSASTK (pep1) KYFDDSER (pep2)
	4-34	3-22	4	ARDRYHYYDSSGYSKNYRHFDYW	DRYHYYDSSGYSK (pep3)
CP08	1-69	3-10	6	VRGMYASGNYRGSDFFYGMDVW	GMYASGNYR (pep4)
				VRGLYASGNFRGSDFFYGMDVW	GLYASGNFR (pep5)
				VRGLYASGSYRGSDFFYGMDVW	GLYASGSYR (pep6)
	1-69	6-13	6	ARVGAPIERTSSSWHYYYYGMDVW	VGAPIER (pep7)
	4-31	6-6	4	ARGFYEVYSSPTIKEYYFDYW	GFYEVYSSPTIK (pep8)
	3-7	3-16	4	ARVKINPYYDYVWGSYRYSRILDYW	YDYVWGSYR (pep9)
CP63	1-69	3-22	4	ARLGRGDYDSSGYYKVYFDYW	GDYDSSGYYK (pep10)
FCP01	1-46	3-10	6	SRGITLVQGVVRALRPGSKEYYYYGLDVW	YCSRGITL (pep11)
					GITLVQGVVR (pep12)
					GFTLVQGVVR (pep13)
					VQGVVRAL (pep14)
					ALRPGSKEYY (pep15)
					TLVQGVVR (pep16)



Α

# Extended Data Figure 4: MS-based quantification of immunoprecipitated S1-specific clonotypic antibodies.

(A) Combined B cell receptor sequencing and proteomics platform enables identification and quantification of circulating anti-S1 antibodies. S1-specific IgG was purified from plasma of SARS-CoV-2 convalescent subjects using antigen-coupled magnetic beads and heavy chains subject to LC-MC/MS. Peptide spectra are searched against B-cell receptor sequencers recovered from single sorted S-specific memory B cells from matched individuals to identify clonotypes based upon CDR-H3 amino acid sequence. Clonotype specific peptides are then used as barcodes for relative quantitative parallel reaction monitoring (PRM) for tracking in longitudinal plasma samples. Targeted peptides are monitored during elution from HPLC and individual peptides quantified based on abundance chromatography curves. (B) Clonotypes identified based on matched CDR-H3 sequences from S1-specific plasma IgG and B cell receptor sequences from SARS-CoV-2 convalescent subjects (n=4). (C) Longitudinal changes in the relative plasma abundance of anti-S1 clonotypes within four convalescent subjects over time. The quantity of each reference peptide is expressed as area under the curve (AUC) derived from extracted ion chromatography.



# Extended Data Figure 5: Activation status of S-specific IgG+ memory B cells.

(A) Memory B cell phenotypes identified by CD21 and CD27 co-staining of S+CD19+CD20+IgD-IgG+ B cells (red) overlaid onto parental CD19+CD20+IgD-IgG+ B cells (black) and (B) the corresponding frequencies of "activated" (CD27+CD21-) or resting (CD27+CD21+) in in PBMC samples were assessed longitudinally (n=31 subjects).



Extended Data Figure 6: RBD-specific memory B cell dynamics.

(A) Frequencies of RBD-specific IgG+, IgA+ or IgM+ memory B cells as a proportion of CD19+CD20+IgD- B cells in PBMC samples were assessed longitudinally. (B) Comparison of RBD-specific IgG+, IgA+ or IgM+ memory B cell frequencies at the earliest and latest timepoint available for each individual (n=31). Statistics assessed by two-tailed Wilcoxon test.



# Extended Data Figure 7: Fitting of the kinetics of S- and RBD-specific memory B cell responses over time.

The best-fit half-lives are shown for the fitting of the growth and/or decay of S- or RBD-specific memory B cells (n=31 subjects). Two-phase decay is indicated by red (before day 70) and blue (after day 70) shaded areas. No shading indicates where a single-phase decay model was used to fit the data.



Days post-onset

# Extended Data Figure 8: Fitting of the decline in SARS-CoV-2-specific T cells over time.

The best-fit half-lives are shown for the fitting of the decay of cTFH, CD4+ Tmem and CD8+ Tmem specific to total S (S1+S2 responses combined), S1 or S2 peptide pools (n=31 subjects). In all cases decay was fit with a single-phase decay model with the half-lives shown.











D





S1

S2

**Final Visit** p=0.0021 2.5 80 06 0.0

S1

S2

# Extended Data Figure 9: S1 and S2-specific CD4+ T cell responses.

(A, C) Representative staining of AIM markers following S1 and S2 peptide pool stimulation among (A) cTFH (CD3+CD4+CD8-CD45RA-CXCR5+) or (C) CD4+ Tmem cells and longitudinal cohort analysis (n=31). (B, D) Comparison of S1 or S2-specific (B) cTFH or (D) CD4+ Tmem responses at the earliest and latest visit for each participant, as well as paired frequency of S1 versus S2 responses at the initial or final visit (n=31). Statistics assessed by two-tailed Wilcoxon test.

Α

#### CD4+CD45RA-CXCR5-



# Extended Data Figure 10: Epitope-specific CD4+ T cell responses.

(A) Representative staining of AIM markers following S1 or S2 peptide pool or individual peptide stimulation among the CD4+ Tmem population. (**B**,**C**) Longitudinal peptide-specific frequencies in individual subjects (n=9; solid line, CD4+ Tmem; dashed line, cTFH) for whom (**B**) multiple or (**C**) single epitopes were identified.



#### **Isotype staining**



# CD21/27 staining



# **Probe staining**



# Supplementary Fig. S1: Gating strategy for resolving antigen-specific B cells and surface isotypes.

After doublet exclusion (FSC-A vs FSC-H) and lymphocyte gating (FSC-A vs SSC-A), live CD19+IgD-CD20+ B cells were gated based on surface immunoglobulin expression (IgM, IgG, IgA). Binding to SARS-CoV-2 spike (S) and/or SARS-CoV-2 RBD probes was assessed for each population. Memory B cell phenotypes were identified by CD21 and CD27 co-staining.



**Supplementary Fig. S2:** Gating strategy for quantifying antigen-specific T cells. Lymphocytes were identified by FSC/SSC, followed by doublet exclusion (FSC-A vs FSC-H), and exclusion of dead or CD20+ cells. After gating on CD3, single positive CD4 or CD8 T cell subsets were identified. CD8 Tmem were gated as non-naïve (CD27+CD45RA+) cells, and assessed for co-expression of CD69 and CD137 following stimulation. CD4 T cells were gated as cTFH (CXCR5+CD45RA-) or Tmem (CXCR5-CD45RA-), and assessed for co-expression of OX-40 and CD25 following stimulation.



Supplementary Fig. S3: Representative annotated MS/MS spectra (left panel) and their corresponding extracted ion chromatograms (XICs; right panel). The peptides used in PRM analyses are the matched clonotypic CDR-H3 peptides (pep1-16). Underlined amino acid indicates a post translational modification:  $\underline{M}$  (oxidised methionine),  $\underline{W}$  (oxidised tryptophan),  $\underline{K}$  (carbamidomethylated lysine),  $\underline{D}$  (carbamidomethylated aspartate),  $\underline{C}$  (carbamidomethylated cysteine), and  $\underline{Y}$  (acetylated tyrosine). The sequences, m/z and z of each individual peptides are shown on the top of their annotated MS/MS spectra. Matched b ions are indicated in blue and y ions are in red. m=mass, z=charge.